Skin aging is driven by both intrinsic (genetic and cellular) and extrinsic (sun, pollution) factors, but the molecular mechanisms remain incompletely understood. This study investigated whether epigenetic changes—chemical modifications to DNA that affect gene expression without changing the DNA sequence itself—are a conserved hallmark of skin aging across diverse populations. The researchers hypothesized that if aging signatures are universal, they could develop a single biological clock and intervention applicable across ethnicities.
The team took two complementary approaches. First, they collected skin samples from 17 donors of diverse ethnicities using a tape-stripping method and performed DNA methylation profiling to build an epidermal methylation clock—a molecular predictor of biological age. Second, they conducted an 8-week clinical trial with 60 participants (Fitzpatrick skin types I-VI) who applied a serum containing dihydromyricetin (DHM), a natural compound claimed to inhibit epigenetic aging. They measured epigenetic age, skin roughness, wrinkle depth, and dermal echogenicity (ultrasound density) at baseline and after treatment.
Key findings: age-dependent DNA hypermethylation patterns were conserved across ethnic groups and primarily affected genes involved in keratinocyte (skin cell) health. The newly developed epidermal clock successfully predicted biological age across diverse backgrounds. Topical DHM treatment reduced epigenetic age and was associated with clinical improvements: reduced roughness, diminished wrinkle visibility, and increased dermal echogenicity—suggesting structural skin improvement.
However, several limitations warrant caution. The sample sizes are modest: only 17 donors for the methylation profiling and 60 for the clinical trial, with no randomized control group receiving placebo. The study lacks a true control arm, making it impossible to distinguish DHM effects from natural skin recovery or placebo effects. No mechanistic details explain *how* topical DHM penetrates the epidermal barrier or modulates methylation in living skin. The follow-up period (8 weeks) is short; durability and long-term safety are unknown. There is no mention of preregistration or data availability statements, reducing transparency.
This work adds to growing evidence that epigenetic clocks can be applied across populations, which is scientifically valuable. However, the clinical translation—that a topical compound can meaningfully reverse epigenetic aging—requires independent replication in larger, placebo-controlled trials. The paper reads as promising preliminary evidence rather than definitive proof that DHM reverses skin aging. The inclusion of diverse phototypes is commendable and addresses a gap in aging research, but the single-arm design and lack of mechanistic validation limit confidence in causal claims.
0 Comments
Log in to join the discussion.